Immunotherapy, precision medicine, changes that affect tumors … Over 450 debates on national and international experts in Valencia have taken the latest advances in the exploration and excavation of tower tower , on December 13 and 14 at the 26th International Symposium "Raise The Treatment of Digestive Tumors, one of Europe's most important science posts, organized by the Deacon Protection Agency Digestive (TTD).
The chairman of the TTD Group, Professor Enrique Aranda, Head of Reina Sofía University Hospital Service in Córdoba, stressing the importance of "organizing international meetings, such as this Siùposium, to optimize the latest developments, excavation and excavation of tower, as well as future research sequences". The publications in this area are particularly relevant, as the most common family of strange illnesses in the Western countries, including Spain, where around 60,000 people are judged every year with an excavator tumbler. Only in the Valencian Community that has more than 5,000 annual judgments made.
The largest colorectal cancer of these towers, in Spain, has more than 34,000 new cases in 2017 (20,600 in males and 13,700 women). Gastric cancer is followed by about 8,300 new cases per year, pancreatic cancer, with 6,760 annual reports and liver, with 4,500 cases in men and 1,600 in women. Esophageal cancer is rarely less, with around 2,200 cases annually.
Although there are not many of the highest examples, pancreatic cancer is dying at two years over 95%, according to Co-ordinators of its Company, Dr. María José Safont, Medical Oncological Service of the University of Valencia General Hospital, and Professor Andrés Cervantes, of the Clinical Oncology Service of the University Medical Hospital in Valencia. "These advances are timid, but independent," they say. These include improving the quality of the surgery for patients with local diseases and epilepsy, postoperative cemotherapy for patients who are ill-treated. assaulted, pre-operative chemotherapy for specific patients and patients; Progress in treatment with long-term meta- tions that promotes continuous improvement
Here are some of the advances that are presented in Symposium of Digestive Tumors, but among the main scientific newspapers, these were mainly associated with the most excavated cancer, colorectal cancer. In particular, its Company Co-ordinators have a & # 39; stressing that, "in the last two years, there has been a very relevant information that has emerged from international surveys with a large Spanish partnership in which it is recommended that it is possible to reduce the management of advanced chemotherapy from six to three months in sub-groups of colon cancer patients. "This means" reducing many of the toxic effects that have been using long chemotherapy ", such as toxicity, diarrhea and mucositis.
In addition, co-ordinators have recently identified immunotherapy products that will be discussed at the Symposium. "The role of immunotherapy with PDL1 obstruction in these patients has a post-aesthetic analogy that includes microsatellite insecurity, a biological sub-field easily identifiable," they say. These patients may have a greater impact on immunotherapy than with current cures, "explain the co-ordinators.
In colorectal cancer, beyond scientific advances, co-ordinators can identify good results of prevention measures. Among them, it was established in the Valencian Community, among others, of a collar cancer screening test by; deciding the wild blood in the population over the age of 50. Free trial "which helped to test patients with pre-scheduled shirts and neoplasms in earlier stages, with the progress in this progress," said Dr. Safont.
Regarding the advances in other tumors, local diagnosis can investigate the "proper assessment and choice of patients who can benefit from conservation management." Similarly, "the latest advances in hepatobiliary tunnels and neuroendocrine will be examined from a multi-disciplinary perspective", which emphasizes Dr. Cervantes. The role of immunotherapy in gastroesophageal tunnels will also be addressed.
New international search lines
Hundreds of oncologists from all devolved communities attend the 26th International Symposium in Valencia, with international experts (in particular Europe and Latin America, in particular). A third of the international speakers, from the United States, the United Kingdom, Germany, Italy, and # 39; Belgium, Sweden and Holland. Amongst these international exhibitions, Professor Giulia Siravegna, of Cancer of Turin's Research and Medicine Institute, reveals the clonal change of suburbs. In his exhibition, he will talk about what happens when a tumor or a tumor complexion occurs; proceeded after treatment with medications directed according to molecular targets. "This new knowledge section allows us to understand that the tumor is not always the same as the natural course of the illness," explain their communication co-ordinators. "Following the promotion of Darwinian model, tumors will acquire new abilities to get rid of their new medication and resistant medicines. But these new abilities can be made aware of other treatments which are directed against new tenants or molecular changes, "said Dr. Safont. So, "future treatment will be very spectacular and it has to change with a criterion of medication for the changes to illnesses", they will explain. "Progressive and medical remedies will help to respond to this new challenge."
Results of clinical trials
As well as carrying out a number of clinical trials, the TTD Group has been one of the first collaborative groups in the detect and detect tumor cell (CTC) that is circulated in patients with an eye-catching cancer and in deciding the organizational status of the gene RAS.
As a result of this work, the TTD will appear in the coming months that the final results of the VISNU project, participating in 600 patients, can be the originating world-wide work, according to the profile of each patient, which is the optimal optimal option according to the CTC number and the presence of non-variant methods in several genera (RAS, BRAF and PI3K).
Similarly, the results of the RE_ARRRANGE survey, an international recommendation led by the TTD that will take into account the participation of Italy and France, with a partnership of 300 patients, who have The aim is to explore different methods – at the next European Oncology Congress. a medical guide that could improve the treatment and treatment of patients to have a better image of safety and surrender in the development of a post-graduate bilingual diagnostic cancer. first two trips.
On the other hand, the co-ordinators also indicate, "in the field of personal medication," the PLATFORM-B study of fluid biopsy research on patients with intestinal cancer, candidates for anti- EGFR.
It also continues with the exam line, & # 39; looking for the best dose to achieve the highest efficacy with the lower toxicity of patients with AFEMA's diagnostic diagnostic diagnosis and the SEQUENCE study in the first line of severe metastatic cancer in cancer . pancreas analyzing the medicine order with nab-paclitaxel and gemcitabine by FOLFOX.